Document Detail


Current status of pharmacological thrombolytic therapy and mechanical thrombectomy for the treatment of acute deep venous thrombosis.
MedLine Citation:
PMID:  19149540     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Deep venous thrombosis (DVT) is a highly prevalent clinical problem associated with significant mortality and morbidity. In the United States alone, it is estimated that DVT affects approximately 50 per 100,000 people per year. This results in >600,000 inpatient and outpatient treatments per year and accounts for approximately 100,000 deaths from thromboembolic complications. Post-thrombotic syndrome (PTS) is associated with serious long-term physical, social and economic sequelae for patients. In this article, we attempt to perform a contemporary review of the literature pertaining to the use of thrombolytic therapy and endovascular thrombectomy in the treatment of acute DVT.
Authors:
Thomas J Kiernan; Beatriz Cepeda; Gareth D Kiernan; Bryan P Yan
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular & hematological agents in medicinal chemistry     Volume:  7     ISSN:  1875-6182     ISO Abbreviation:  -     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-19     Completed Date:  2009-04-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266881     Medline TA:  Cardiovasc Hematol Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  12-8     Citation Subset:  IM    
Affiliation:
Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Humans
Thrombectomy / methods*,  trends
Thrombolytic Therapy / methods*,  trends
Venous Thrombosis / complications,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The intermediate-conductance Ca2+ -activated K+ channel (KCa3.1) in vascular disease.
Next Document:  Nucleotide-derived thrombin inhibitors: a new tool for an old issue.